BRANMOOR
THURSDAY · 14 MAY 2026

FDA Recall D-0135-2024

Cardinal Health Inc. · Dublin, OH

Class I — life-threatening Ongoing 926 days on record

Highest impact — Class I recall — FDA determination of strong likelihood of serious adverse health consequence or death. Distribution is nationwide and the recall remains in progress.

Product

LEADER brand Dry Eye Relief (Polyethylene Glycol 400, 0.4% Propylene Glycol, 0.3%); 0.33 FL OZ (10 mL) dropper bottle, Sterile, Distributed By Cardinal Health, Dublin, Ohio 43017, Made in India NDC: 70000-0088-1

Lot / code: ALL LOTS

Quantity: 11,782 bottles

Reason for recall

Non-Sterility: FDA found insanitary conditions and positive bacterial test results from environmental sampling at the manufacturing facility.

Recall record

Recall number
D-0135-2024
Classification
Class I
Status
Ongoing
Voluntary or mandated
Voluntary: Firm initiated
Firm notification
Press Release
Distribution
Nationwide in the USA
Recall initiated
2023-10-31
Classified by FDA Center
2023-12-01
FDA published
2023-11-29
Recalling firm
Cardinal Health Inc.
Firm location
Dublin, OH

Drug identification

Brand name(s)
DRY EYE RELIEF
Generic name(s)
POLYETHYLENE GLYCOL AND PROPYLENE GLYCOL
Manufacturer(s)
CARDINAL HEALTH 110, LLC. DBA LEADER
NDC(s)
70000-0088
Route(s)
OPHTHALMIC

Operational response

A Class I recall indicates a strong likelihood of serious adverse health consequence or death. Pull affected lots from active dispensing immediately. Segregate inventory in a marked, locked location pending destruction or return. If product has already been dispensed, identify affected patients and contact them by your standard recall-notification protocol.

For the official FDA enforcement record, see FDA's Recall Search.

‹ All recalls